| Full Name | Sandy Whitman |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 1175 Pine St, Arcadia, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386131258 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 779 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sandy Whitman, 4109 Highway 98 W, Summit, MS 39666-9132 Ph: (601) 276-3909 | Sandy Whitman, 1175 Pine St, Arcadia, LA 71001-3121 Ph: (318) 263-9243 |
News Archive
Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, working in collaboration with researchers from the Harvard Medical School, today announced that the Journal of Clinical Oncology has published a paper showing the frequency of germline mutations in 25 cancer susceptibility genes among patients with breast cancer.
New research from the University of Wisconsin-Madison explains why the incurable brain cancer, glioblastoma multiforme (GBM), is highly resistant to current chemotherapies.
What is the relationship between COVID-19 and the brain? A new review published in Tropical Biomedicine summarizes the key findings on how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes severe COVID-19 infection, disrupts brain activity and produces a range of long-term neurological disorders.
Nearly five million Americans live with heart failure, with as many as 700,000 new cases diagnosed each year. In addition to lifestyle factors, scientists have shown that heart failure has a strong heritable component, but identifying the responsible genes has been a major challenge. Now, new research has identified a common genetic risk factor for heart failure in Caucasians that is also linked to kidney function.
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
› Verified 8 days ago
Kelsey Poche Abbas, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1956 1st St, Arcadia, LA 71001 Phone: 318-236-9416 | |
Breayn Lindsey Hardy, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1175 Pine St, Arcadia, LA 71001 Phone: 318-263-4700 | |
Katie Golden, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1175 Pine St, Arcadia, LA 71001 Phone: 318-263-9243 | |
Mrs. Della Middleton, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1956 1st St, Arcadia, LA 71001 Phone: 318-263-9416 | |
Cara Waits, MCD-CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2052 3rd St, Arcadia, LA 71001 Phone: 318-263-9277 Fax: 318-263-9277 | |
Emily Murhpy, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1355 6th St, Arcadia, LA 71001 Phone: 318-263-9581 |